ZIOPHARM Oncology (NASDAQ:ZIOP) posted its earnings results on Thursday. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.34), Fidelity Earnings reports.
NASDAQ ZIOP opened at $4.44 on Friday. The company has a fifty day moving average price of $4.22 and a 200-day moving average price of $4.88. The firm has a market cap of $794.72 million, a price-to-earnings ratio of -9.25 and a beta of 2.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $7.25.
Several research firms have recently issued reports on ZIOP. HC Wainwright reiterated a “buy” rating and issued a $6.50 target price on shares of ZIOPHARM Oncology in a research note on Wednesday, October 2nd. ValuEngine lowered shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 2nd. Raymond James set a $6.50 target price on shares of ZIOPHARM Oncology and gave the stock an “outperform” rating in a research note on Friday. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Finally, Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. ZIOPHARM Oncology currently has a consensus rating of “Hold” and an average price target of $6.25.
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: Cost of Capital Explained
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.